Most people have never heard of SR-17018, and that's exactly why it's worth writing about. It's one of a growing number of laboratory-developed opioids that were never meant to be sold to the public but are increasingly turning up as "research chemicals" ordered online. If you or someone you love is using unfamiliar substances like this, understanding the risks — and knowing help exists — matters.
SR-17018 is an opioid. If you suspect an overdose, call 911 and give naloxone (Narcan) right away, then stay with the person. Naloxone is still the correct first response for any suspected opioid overdose.
What is SR-17018?
SR-17018 is a synthetic compound first developed in academic pharmacology research as a "G-protein–biased" mu-opioid receptor agonist — part of an effort to study whether opioids could relieve pain with fewer side effects. It is not an approved medication, is not prescribed, and has never been established as safe for human use. In other words, it belongs in a lab, not in a person.
Despite that, compounds like SR-17018 have begun circulating in the gray market of novel psychoactive substances, sold as powders or "not for human consumption" research chemicals. Because it acts on the same receptors as morphine, fentanyl, and heroin, it produces opioid effects — and carries opioid risks.
Why it's especially risky
- It's unregulated and untested in people. There are no dosing standards, no quality control, and no way to know what's actually in a product sold this way.
- Potency and purity are unknown. A tiny difference in an unlabeled powder can be the difference between a dose and an overdose.
- It causes opioid dependence. Regular use leads to tolerance and physical dependence, and stopping brings on opioid withdrawal.
- Overdose response can be less predictable. It is still an opioid, so naloxone remains the right first step — but with novel, high-potency compounds, more than one dose and immediate 911 care may be needed.
"A powder with no label and no oversight can't tell you how strong it is. Your body finds out the hard way."
Signs of opioid dependence & withdrawal
Because SR-17018 acts like other opioids, dependence and withdrawal follow the familiar opioid pattern. Withdrawal usually begins within 12–24 hours of the last dose and can include:
- Anxiety, restlessness, and irritability
- Muscle aches, sweating, and chills
- Nausea, stomach cramps, and diarrhea
- Insomnia and intense cravings
The physical symptoms typically ease within about a week; cravings and low mood can last longer, which is why ongoing support matters.
Getting help in Philadelphia
Whether the substance is a familiar opioid or an obscure research chemical like SR-17018, the path out is the same — and it works. Because these compounds act on opioid receptors, clinicians can use the evidence-based tools proven for opioid use disorder, including medication such as buprenorphine (Suboxone) to manage withdrawal and cravings. Philadelphia Recovery Solutions coordinates medically supported detox when it's needed and continues care through our outpatient (IOP) and partial hospitalization (PHP) programs in South Philadelphia.
Philadelphia Recovery Solutions provides outpatient drug & alcohol treatment (IOP and PHP) for opioid use — including novel and research-chemical opioids — at our South Philadelphia location. Same-week intake available and most major insurance accepted. Get help today or call (215) 770-1694.
In crisis right now? Call or text 988 for the Suicide & Crisis Lifeline, or call 911 for an emergency.
Schmid, C.L., et al. (2017). Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. — National Institute on Drug Abuse. Novel synthetic opioids. nida.nih.gov — U.S. Drug Enforcement Administration. Emerging threats & novel psychoactive substances. dea.gov. Research-chemical availability and risks evolve quickly; this article is for educational purposes and does not constitute medical advice.